Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. Forbion is a signatory to the United Nations Principles for Responsible Investment further demonstrating its philosophy that investments in companies should positively impact the health and well-being of patients. Forbion currently manages over €1.8 bn across nine closed-end funds, including its €460m Forbion V Fund, which started investing in 2021, and its €360 million Forbion Growth Opportunities Fund I which started investing in 2020. As of April 2021, Forbion holds 27 active portfolio companies of which 4 are listed and 23 are private, bringing its investments to just over 70 companies to date. Forbion’s investors include the European Investment Fund (EIF), notably through its European Recovery Programme (ERP), LfA, the Dutch Venture Initiative (DVI) and AMUF facilities, and the Kreditanstalt für Wiederaufbau (KFW) through the ERP – Venture Capital Fondsfinanzierung facility. Forbion operates a joint venture with BioGeneration Ventures (BGV). Since their inception in 2006, BGV has managed €250 million across its four funds. BGV is looking for seed and early stage investment opportunities in biotech companies for BGV IV which was launched in April 2020. The Forbion team consists of over thirty people across three offices in The Netherlands, Germany and Singapore.